When it comes to cancer research, there are numerous companies that specialize in this demanding industry. Did you know that the United States is home to one of the leading cancer research organizations in the world? This company is known as Seattle Genetics, and it is on a mission to save lives. President and CEO Clay Siegall is the captain of the ship, and he is steering this gigantic ship to success through rigorous research, drug development and innovative technology. The company’s track record speaks for itself as it has produced some of the best cancer fighting drugs in history. These drugs are antibody drug conjugates, and they are a supreme game changer.
Dr. Siegall is a well-respected individual thanks to his knowledge, expertise and passion. He has worked with some of the most prominent names in the industry including the National Institute of Health, Bristol Myers Squibb and the National Cancer Society. Siegall’s business knowledge and entrepreneurial skills have landed strategic licensing deals with GlaxoSmithKlien, AbbVie and Genentech. With this deal, the company’s medications can now be distributed on a worldwide scale. Siegall has stated that Seattle Genetics became profitable around 10 years ago. Antibody Based Therapies are changing the game by saving lives. These therapies outperform every other cancer fighting medication that’s on the market today. ADCETRIS, the company’s top drug, has brought in over $350 million by itself.
Clay Siegall is doing his part to better mankind. He has a Ph.D in Genetics from George Washington University, and he has a B.S. in Zoology from the University of Maryland. The guy has written over 70 successful publications, and he currently holds up to 15 patents. When it comes to raising capital, Siegall has definitely put in the hard work. As of today, he has helped the company raise over $1 billion through private and public funding.